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Abstract
Interleukin-18 (IL-18) is a proinflammatory cytokine of the interleukin-1 family which is upregulated after cerebral
ischemia. The functional role of IL-18 in cerebral ischemia is unknown. In the present study, we compared infarct
size in IL-18 knock-out and wild-type mice 24 hours and 48 hours after 1-hour transient middle cerebral artery
occlusion (tMCAO). Moreover, the functional outcome was evaluated in a modified Bederson score, foot fault test
and grip test. There were no significant differences in infarct size or functional outcome tests between wild-type
and IL-18 knock-out mice. These data indicate that the early inflammatory response to cerebral ischemia does not
involve IL-18, in contrast to other interleukin-1 family members such as interleukin-1.
Background
There is increasing evidence that inflammatory pro-
cesses play a detrimental role in ischemic stroke [1,2].
On the other hand, the postischemic immune response
may also be beneficial with respect to neuroprotection
and tissue remodelling. The proinflammatory cytokine
IL-18 is an interleukin-1 family member identified as
and named interferon-g-inducing factor [3,4]. The
effects of IL-18 are complex and pleiotropic involving
activation of T cells and NK cells in autoimmune disor-
ders (for review, see Reddy [5]). In the central nervous
system, IL-18 can locally be produced by activated
microglia [6,7]. Increased IL-18 serum levels have been
detected within 24 hours in patients with acute ischemic
stroke [8], and elevated IL-18 plasma levels at 48 hours
were associated with unfavorable clinical outcome at 3
months [9]. Moreover, in hypoxic-ischemic brain injury
in neonatal rats, an early IL-18 activation (already within
hours) and a progressive increase for at least 14 days
have been described [10]. At 3 days after hypoxia-ische-
mia, IL-18 deficiency has been shown to ameliorate
infarct volume and grey matter injury [10] as well as
white matter injury [11] in neonatal mice. These studies
suggest that IL-18 may play a pathophysiological role in
stroke development. To elucidate a functional role of
IL-18 in cerebral ischemia we investigated infarct size
and functional outcome 24 hours and 48 hours after
tMCAO in adult mice with IL-18 deficiency.
Methods
Animal studies were conducted in accordance with
institutional guidelines and approved by the appropriate
authorities (Regierung von Unterfranken). Wild-type
and IL-18 knock-out mice that had been generated [12]
and backcrossed onto BALB/C mice [13] as described
were kindly provided by Drs. X-Q Wei and FY Liew,
Glasgow, Scotland, and bred and raised in our labora-
tory animal facility. A total of 35 wild-type and 29 IL-18
knock-out animals (plus additional 11 wild-type and 10
knock-out mice for laser-Doppler flowmetry and ink
perfusion) were used.
Mice weighting 18-24 g were subjected to transient
focal cerebral ischemia in the right middle cerebral
artery (MCA) territory for 1 hour using the intraluminal
suture MCA occlusion method [14]. In brief, mice were
anesthetized with 2% to 2.5% enflurane in a 70% N2O/
30% O2 mixture. A servo-controlled heating blanket was
used to maintain core body temperature close to 37°C
throughout surgery. A silicon rubber-coated 6.0 nylon
monofilament (Doccol, Albuquerque, NM) was inserted
into the right common carotid artery and advanced via
the internal carotid artery to occlude the origin of the
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MCA territory. The occluding filament was removed
after 1 hour to allow reperfusion. Animals were sacri-
ficed 24 hours or 48 hours after tMCAO. Brains were
harvested and 2 mm-thick coronal slices were sectioned
in a mouse brain matrix. After staining with 2% 2,3,5-
triphenyltetrazolium chloride (TTC; Sigma-Aldrich, St.
Louis, MO) in PBS, the pale infarctions were readily dis-
cernable from the brick-red non-ischemic areas and pla-
nimetric measurements were obtained using the ImageJ
software package (available at http://rsb.info.nih.gov/ij/;
National Institutes of Health, Bethesda, MD). The calcu-
lated lesion volume was corrected for brain swelling as
described by Ginsberg et al. [15].
Additionally, we assessed the functional outcome in
representative subsets of the animals. Immediately after
recovery from anesthesia, and 24 hours and 48 hours
later, a modified Bederson score [16] was determined
according to the following scoring system: 0, no deficit; 1,
forelimb flexion; 2, as for 1, plus decreased resistance to
lateral push; 3, unidirectiona lc i r c l i n g ;4 ,l o n g i t u d i n a l
spinning or seizure activity; 5, no movement. 24 hours
and 48 hours after surgery, the foot fault test and grip test
were performed. The foot fault test was done as described
by Gibson et al. [17], with the following modifications:
Mice were placed on an elevated grid with 1.44 cm
2 open-
ings and allowed to take 25 paired steps. Animals not
moving spontaneously for at least 25 steps were excluded.
The number of foot faults of the ipsilateral and contralat-
eral limbs was counted. Foot faults were given as the per-
centage of contralateral (left) limb foot fault errors of all
errors made. The grip test, also known as string test, was
adopted from Moran et al. [18], with modified scoring
system. For this test, the mouse was placed midway on a
string between two supports and rated as follows: 0, falls
off; 1, hangs onto string by one or both forepaws; 2, as for
1, and attempts to climb onto string; 3, hangs onto string
by one or both forepaws plus one or both hindpaws; 4,
hangs onto string by fore- and hindpaws plus tail
wrapped around string; 5, escape (to the supports).
Laser-Doppler flowmetry (Moor Instruments, Axmin-
ster, United Kingdom) was used to monitor cerebral
blood flow in 6 IL-18 +/+ and 5 IL-18 -/- animals
before surgery (baseline), immediately after tMCAO,
and 5 minutes after removal of the occluding monofila-
ment (reperfusion). For this, a flexible laser-Doppler
probe was positioned perpendicular to the exposed skull
2 mm posterior and 6 mm dexterolateral to the bregma,
corresponding to the laser-Doppler probe position in
murine MCA occlusion reported by Connolly et al. [19].
These animals were not included in the infarct size and
functional outcome evaluations, because laser-Doppler
flowmetric measurements in addition to tMCAO inevi-
tably leads to prolonged operation times.
To exclude anatomic differences that could cause dif-
ferent susceptibility to tMCAO in wild-type and knock-
out mice, we studied the cerebrovasculature in 5 IL-18
+/+ and 5 IL-18 -/- mice. Animals were deeply anesthe-
tized with CO2 and transcardially perfused with 4% paraf-
ormaldehyde and then with black ink (T25; Edding,
Ahrensburg, Germany). After brain removal and over-
night fixation in 4% paraformaldehyde, the circle of Willis
was visualized under a dissecting microscope. Special
attention was paid to the posterior communicating
arteries, whose level of plasticity was rated as described
by Murakami et al. [20]: 0, absent; 1, capillary anastomo-
sis; 2, small truncal vessel; 3, patent. A posterior commu-
nicating artery with a score of 0 or 1 is regarded as
hypoplastic, and with a score of 2 or 3 as normal.
Corrected infarct volumes, data from the functional
outcome tests and from the posterior communicating
artery score, and laser-Doppler flow measurements were
statistically analyzed in two-tailed Mann-Whitney U tests
using Prism 4 (GraphPad Software, San Diego, CA).
Results
Ink perfusion was performed in IL-18 wild-type and
k n o c k - o u tm i c et ov i s u a l i z et h ec o m p l e t ec i r c l eo f
Willis. No gross anatomic differences were noted that
could influence stroke outcome (Figure 1). The score
assessing formation of the posterior communicating
arteries of both hemispheres, which are pivotal in collat-
eral blood flow between the anterior and posterior cir-
culation, did not differ significantly in wild-type and
knock-out mice (median of 2 in both groups; p = 0.91).
Moreover, Laser-Doppler flowmetry ensured technical
accuracy and similar basic characteristics in IL-18 +/+
and IL-18 -/- mice, since it did not show any significant
differences between wild-type and knock-out animals.
After right MCA occlusion, there was a similar substan-
tial reduction of right hemispheric cerebral blood flow
(median, 16.15% and 16.4%, respectively; p = 0.93). The
blood flow recovered to a median of approximately 50%
of baseline blood flow already within minutes after
removal of the occluding intraluminal monofilament
(median, 48.9% and 50.9%, respectively; p = 1.00).
We next assessed the influence of IL-18 on infarct size
and on functional outcome. There were no significant
differences in edema-corrected infarct size on standar-
dized TTC-stained brain slices between wild-type and
IL-18 knock-out mice after 24 hours (median, 79.25
mm3 and 86.1 mm
3, respectively; interquartile range,
41.9 - 90.3 mm
3 and 38.1 - 95.6 mm
3, respectively; p =
0.51) or 48 hours (median, 93.05 mm
3 and 85.2 mm
3,
respectively; interquartile range, 75.3 - 104.6 mm
3 and
73.9 - 98.7 mm
3, respectively; p = 0.36). These results
are presented in Figure 2A. The functional outcome
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Page 2 of 5Figure 1 Ink perfusion. Images of a BALB/C wild-type mouse brain (A) and of a brain from an interleukin-18 knock-out mouse on a BALB/C
background (B) with ink-perfused cerebrovasculature.
Figure 2 Infarct volumes and functional outcome. Infarct volumes (A) and functional outcome scores (B: modified Bederson test score; C:
foot fault test; D: grip test score) of interleukin-18 wild-type and knock-out mice. The results are diagrammed as whisker boxes with medians.
Boxes represent interquartile ranges and whiskers indicate extreme values. The p values resulting from Mann-Whitney U tests are given; all p
values were greater than 0.05 and were thus considered insignificant. Abbreviations: wt, wild-type animals; ko, interleukin-18 knock-out animals;
n, number of animals; 0 h, 0 hours (postoperatively after recovery from anesthesia); 24 h and 48 h, 24 hours and 48 hours after 1-hour middle
cerebral artery occlusion.
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compared to IL-18 -/- mice, too (Fig. 2B, C, D).
Discussion
As principal finding, we show that deficiency of IL-18
does not protect mice from ischemic brain damage after
tMCAO. These findings are surprising given the
reported upregulation of IL-18 blood levels in stroke
patients [8,9] associated with adverse clinical outcome
[9] and the profound impact of IL-18 in experimental
neonatal stroke [10,11]. However, two recent nested
case-control studies have not confirmed an association
of IL-18 with increased risk of stroke in older people
[21] or with recurrent stroke [22]. Moreover, our data
are in accordance with a previous study by Wheeler et
al. showing no differences in infarct size at 24 hours
between wild-type and IL-18 -/- mice on a C57BL/6
background subjected to 15 and 30 minutes of tMCAO
which leads to smaller infarcts than 1 hour occlusion
time [23]. We extend this previous study by applying a
longer tMCAO time (1 hour) leading to infarcts invol-
ving the entire MCA territory, by assessing functional
outcome and by following infarct development up to 48
hours. Recently, IL-18 expression and activation has
been described already at 24 hours in a thromboembolic
murine stroke model [24]. In contrast, in the rat, IL-18
mRNA expression was increased later at 48 hours, and
peaked between 7 and 14 days [25]. IL-18 has been loca-
lized to microglia/macrophages within ischemic lesions
[25]. The structurally similar interleukin-1b reached a
peak already within 16 hours and was rapidly downregu-
lated subsequently [25]. Thus, unlike interleukin-1b,I L -
18 seems to be associated with the mid-stage inflamma-
tory response to ischemic brain lesions. Accordingly,
similar findings were reported for traumatic brain injury
in mice: IL-18 was significantly elevated at 7 days, but
not within 4 hours to 24 hours, after experimental
closed head injury as compared to sham treatment [26].
Inhibition of IL-18 by IL-18-binding protein resulted in
improved neurological recovery by 7 days, while brain
edema at 24 hours was not reduced [26]. The cytokine
response in neonatal rodents subjected to hypoxic-
ischemic brain injury may differ. Here, a significant
mRNA elevation for IL-18 has been reported to occur
already at 3 hours, but also progressively increased until
day 14 [10]. In summary, our findings in adult IL-18
knock-out mice support the notion that IL-18 is not
functionally relevant for early stroke development, but
may play a role in late-stage neuroinflammation after
stroke which awaits further elucidation.
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